Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Plos One|October 12, 2020
Assessing multiple score functions in Rosetta for drug discoveryShannon T Smith, Jens MeilerPlos One|May 31, 2022
PlaceWaters: Real-time, explicit interface water sampling during Rosetta ligand dockingShannon T Smith, Laura Shub, Jens MeilerPsychological Assessment|December 12, 2017
Intentional inattention: Detecting feigned attention-deficit/hyperactivity disorder on the Personality Assessment InventoryShannon T Smith, Jennifer Cox, Elyse N Mowle, et al.Biomolecules|March 25, 2022
Structural Comparative Modeling of Multi-Domain F508del CFTREli Fritz McDonald, Hope Woods, Shannon T Smith, et al.Biochemistry|January 10, 2023
Rosetta's Predictive Ability for Low-Affinity Ligand Binding in Fragment-Based Drug DiscoveryElleansar Okwei, Shannon T Smith, Brian J Bender, et al.Bioorganic Chemistry|January 7, 2024
Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory propertiesFabian B Kraft, Jana Enns, Irina Honin, et al.Structure (London, England : 1993)|February 21, 2025
Discovery and characterization of potent macrocycle inhibitors of ubiquitin-specific protease-7Rafael Miranda, Francesca Anson, Shannon T Smith, et al.ACS Chemical Neuroscience|December 2, 2021
Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) InhibitorsJeanette L Bertron, Matthew T Duvernay, Sidnee G Mitchell, et al.Nature Medicine|January 16, 2018
Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical modelsMichael L Schulte, Allie Fu, Ping Zhao, et al.ACS Pharmacology & Translational Science|April 18, 2024
Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual ScreeningShannon T Smith, Jackson B Cassada, Lukas Von Bredow, et al.Pageof 2